ClinicalTrials.gov ID: NCT02071134
Ages Eligible: 18 Years and Older
Sexes Eligible: All
Study Phase: Observational
Study Completion (Estimated): 2028-12
Principal Investigator: Pinky Agarwal, MD, FAAN
Contact Information:
EvergreenHealth Research Department
425-899-5385
EvergreenResearch@evergreenhealthcare.org
Summary:
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.
Eligibility Criteria:
Inclusion Criteria
- Meets criteria established in locally applicable Vercise System Direction for Use
- At least 18 years old
Exclusion Criteria
- Meets any contraindication in the Vercise System locally applicable Directions for Use
Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.
